Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15729481rdf:typepubmed:Citationlld:pubmed
pubmed-article:15729481lifeskim:mentionsumls-concept:C0014834lld:lifeskim
pubmed-article:15729481lifeskim:mentionsumls-concept:C0034428lld:lifeskim
pubmed-article:15729481lifeskim:mentionsumls-concept:C0282215lld:lifeskim
pubmed-article:15729481lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:15729481lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:15729481pubmed:issue1lld:pubmed
pubmed-article:15729481pubmed:dateCreated2005-2-24lld:pubmed
pubmed-article:15729481pubmed:abstractTextWe studied the antimicrobial susceptibility of AmpC beta-lactamase-producing Escherichia coli isolates collected at ten medical institutions in the Kinki area of Japan during a 6-month period (November 2002 through April 2003). Of 2845 E. coli isolates tested, 29 (1.0%) showed a minimum inhibitory concentration (MIC) for cefazolin of more than 8 microg/ml and were three-dimensional extract test positive. In standard inoculum susceptibility tests against these 29 strains, the MIC90s for the four carbapenems tested ranged from 0.06 microg/ml to 0.5 microg/ml, and these compounds were more active than the other beta-lactams, with meropenem being the most active. The MIC90s for beta-lactams, except carbapenems, ranged from 4 microg/ml to 32 microg/ml, with cefepime being the most active. In high inoculum susceptibility tests against these strains, the MIC90s for the four carbapenems and cefepime were 8 microg/ml or less, and these compounds were more active than other beta-lactams. The MIC90s for beta-lactams, except carbapenems and cefepime, were 32 microg/ml or more. The MIC90s for the five quinolones tested ranged from 4 microg/ml to 16 microg/ml, and the order of increasing susceptibility was ciprofloxacin > levofloxacin, gatifloxacin and pazufloxacin > prulifloxacin.lld:pubmed
pubmed-article:15729481pubmed:languageenglld:pubmed
pubmed-article:15729481pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:citationSubsetIMlld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15729481pubmed:statusMEDLINElld:pubmed
pubmed-article:15729481pubmed:monthFeblld:pubmed
pubmed-article:15729481pubmed:issn1341-321Xlld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:SueyoshiNoriy...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:NishioHisaaki...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:KinoshitaShoh...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:HiguchiTakesh...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:SakamotoMasak...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:YamashitaTomo...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:SatohKaoriKlld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:KomatsuMasaru...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:ShimakawaKoic...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:YamasakiKatsu...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:WadaYasunaoYlld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:ToyokawaMasah...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:AiharaMasanor...lld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:KofukuTomomiTlld:pubmed
pubmed-article:15729481pubmed:authorpubmed-author:OritaTamakiTlld:pubmed
pubmed-article:15729481pubmed:issnTypePrintlld:pubmed
pubmed-article:15729481pubmed:volume11lld:pubmed
pubmed-article:15729481pubmed:ownerNLMlld:pubmed
pubmed-article:15729481pubmed:authorsCompleteYlld:pubmed
pubmed-article:15729481pubmed:pagination9-13lld:pubmed
pubmed-article:15729481pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:meshHeadingpubmed-meshheading:15729481...lld:pubmed
pubmed-article:15729481pubmed:year2005lld:pubmed
pubmed-article:15729481pubmed:articleTitleIn vitro activity of beta-lactams and quinolones against AmpC beta-lactamase-producing Escherichia coli.lld:pubmed
pubmed-article:15729481pubmed:affiliationClinical Laboratory, Wakayama Rosai Hospital, 435 Koya, Wakayama, 640-8345, Japan. kyamasaki@gaia.eonet.ne.jplld:pubmed
pubmed-article:15729481pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15729481pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15729481pubmed:publicationTypeMulticenter Studylld:pubmed